Clinical trial
DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia
NCT00241488 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00241488 |
|---|---|
| Title | DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia |
| Official title | : An Open-Label, Randomised, Multi-Centre, Phase IIIb/IV, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia (DISCOVERY) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | Rosuvastatin |
| Enrollment | 1,362 |
| Start date | Jun 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Oct 19, 2005 |
| Last update posted | Feb 7, 2008 |
| Countries | China, Hong Kong, Malaysia, South Korea, Taiwan, Thailand |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: